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Zardaverine is a selective inhibitor of phosphodiesterase (PDE) III and IV isozymes. It has been shown to 
exert potent bronchodilator effects in animals. In order to study the efficacy and safety in man, a phase II 
clinical trial in 10 patients with partially reversible chronic airflow obstruction was carried out. The trial was 
designed as a double-blind, randomized, five-period change-over study. Zardaverine (at single doses of 1.5 mg, 
3.0 mg, or 6.0 mg), salbutamol (0.3 mg) and placebo were administered by metered dose inhaler on separate 
days. As evaluated by spirometry over a time period of 4 h, salbutamol induced a significant broncho- 
dilatation. In contrast, zardaverine did not improve airway function in these patients. Unwanted effects of the 
study medication were not observed. 
Introduction 
Isozyme selective phosphodiesterase (PDE) in- 
hibitors may represent a new class of drugs for the 
treatment of obstructive pulmonary disease such as 
asthma (1). Most evidence so far suggests that PDE 
III inhibitors. and possibly PDE IV and V inhibitors, 
possess bronchodilator activity. On the other hand, 
inhibitors of PDE IV may suppress the activity of 
inflammatory cells such as neutrophils or eosinophil 
leucocytes (1). Mixed PDE III/IV inhibitors may 
possess, therefore, both bronchodilatory and 
anti-inflammatory properties. 
Zardaverine [6-(4-difluoromethoxy-3-methoxy- 
phenyl)-3[2H]pyridazinone] has been characterized as 
a selective PDE III/IV inhibitor (2-4). In animals, 
zardaverine exhibits both bronchodilatory and anti- 
inflammatory activities (5). Very recently, it has been 
shown that inhaled zardaverine has a modest and 
short-lasting bronchodilatory effect in patients with 
asthma (6). The aim of the present phase II clinical 
study was to investigate the bronchodilatory activity 
of inhaled zardaverine in non-asthmatic patients with 
chronic airflow obstruction (CAO). 
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Methods 
The protocol of the study was approved by an 
independent Ethics Committee and written informed 
consent was obtained from all patients. 
Ten male patients completed the study. None of 
the patients had a history of asthma or showed any 
symptoms typical for asthma at the time of the study. 
None of the patients had ever been treated with 
glucocorticosteroids. Baseline spirometry gave a 
vital capacity of 3.93 1 [2.854.66, median and 68% 
central range; predicted 4.49 1 (3.974.83), and a 
residual volume of 3.19 1 (2.55-6.07; predicted 2.16 1 
(1.67-2.66)]. FEV, was 66% (49-88%) of predicted 
value. The patients showed a 2 10% increase of FEV, 
15 min after inhalation of 0.2 mg salbutamol, and 
also 30 min after inhalation of 6.0 mg zardaverine. 
The reversibility tests were performed on two sepa- 
rate days. In the case of salbutamol, FEV, was 1.84 1 
(1.17-2.38, median and 68% central range) before 
drug inhalation and 2.26 1 (1.50-2.69) after inhala- 
tion of the drug. In the case of zardaverine, FEV, 
was 1.76 1 (1.25-2.45) before and 2.01 1 (1.38-2.85) 
after inhalation of the drug. In this pre-study screen- 
ing, the response to placebo-inhalers was not studied. 
The mean age of the 10 patients was 62 years 
(range 50-74 years); mean body weight was 78 kg 
(range 599100 kg) and mean height was 173 cm (157- 
190 cm) (individual data not shown). None of the 
patients received any concomitant anti-obstructive 
medication during the duration of the study. 
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The study was conducted as a placebo-controlled, 
double-blind, randomized five-period change-over 
study. One of the three doses of zardaverine, salbuta- 
mol or placebo was administered on five separate 
study days. The patients were randomly assigned to 
one of five treatment sequences occurring in a Latin 
square. The study medication was administered by 
three single puffs from a metered dose inhaler (MDI) 
using a spacer device (VolumaticR). Administered 
dosages were 1.5 mg, 3.0 mg and 6.0 mg zardaverine, 
and 0.3 mg salbutamol. The study medication for 
each treatment period was provided in MDIs of 
identical appearance. Before and after inhalation of 
the study medication, lung function was recorded at 
lo-min intervals during the first hour and at 30-min 
intervals during the next 3 h. Resting electrocardio- 
graphic function (ECG) was recorded and routine 
laboratory work-up was carried out before and after 
the treatment period. 
STATISTICAL ANALYSIS 
The primary lung function parameter for the inter- 
ference statistical analysis was FEV,, time-averaged 
between lo-240 min after administration of the 
respective treatment. For each individual, the differ- 
ences between verum and placebo were calculated for 
each time period. The time-averaged difference 
between verum and placebo over the 4-h dose inter- 
val was used to characterize the average effect over 
the dose interval. In addition, the respective values 
time-averaged over the first hour after drug inhala- 
tion were calculated. The ‘maximum effect’ within the 
interval of measurements was defined as the time- 
averaged value of three differences prior to, during 
and after the observed maximum difference. Dura- 
tion and intensity of the ‘maximum effect’ were 
documented. The duration of action defined by a 
10% increase in FEV, was evaluated throughout the 
interval, beginning with the first inhalation and end- 
ing 240 min later. ‘Maximum effect’ and duration of 
effect were considered as secondary characteristics 
with respect to FEV,. 
In order to test for a monotone dose-response 
relationship, the distribution-free Page test (6) was 
applied to the placebo dose and the three zardaverine 
doses in the case of the time-averaged FEV,, and to 
the three zardaverine doses in the case of the placebo- 
adjusted ‘maximum effect’ and duration of effect. The 
significance level of 5% (one-sided) was considered as 
relevant. Descriptive analysis included median and 
68% central range. 
Results 
Figure 1 shows the FEV, profile after administra- 
tion of the study medication. Inhalation of salbuta- 
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Fig. I Mean (n= 10) of pulmonary function profiles 
after inhalation of placebo (0), 1.5 mg zardaverine (A), 
3.0 mg zardaverine (+), 6.0 mg zardaverine (0) or 0.3 mg 
salbutamol (*). 
mol resulted in a clinically significant increase in 
FEV,. In contrast, the FEV, values after inhalation 
of different doses of zardaverine were not statistically 
significant from the placebo response (PzO.05). 
With respect to the time period of lo-240 min, the 
time-averaged FEV, difference between salbutamol 
and placebo was 0.29 1 (Table 1). The corresponding 
value for the first study hour was 0.33 1. In contrast, 
neither a statistically significant increase of FEV, 
(time-averaged lo-240 min and 10-60 min, respec- 
tively) after administration of zardaverine was 
observed (P>O.O5), nor was a dose-dependency for 
zardaverine detected (PbO.05, Table 1). 
The maximum increase in FEV, compared to 
placebo was observed after inhalation of 3.0 mg 
zardaverine, and amounted to 0.17 1 (Table 2). Again, 
this effect of zardaverine was not dose-related 
(P>O.O5). In contrast, inhalation of 0.3 mg salbuta- 
mol resulted in a maximum increase in FEV, of 0.47 1 
at 40 min. This effect of salbutamol lasted up to 
approximately 3 h. The duration of the non- 
significant increase in FEV, after administration of 
1.5 mg, 3.0 mg or 6.0 mg zardaverine, respectively, 
was less than 1 h (Table 2). 
Unwanted effects of zardaverine, for instance on 
the central nervous system, were not observed in this 
short-term study. There was neither a change in any 
of the standard laboratory parameters nor in the 
ECG (data not shown). 
Clinical experience with the use of isozyme selec- 
tive phosphodiesterase inhibitors for the treatment of 
obstructive disease is limited. The results with the 
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Table I Mesors of differences in FEV, between active substance and placebo after inhalation 
of study medication 
FEV, (1) FEV, (1) 
Variable 1 O-240 min 1 O-60 min 
1.5 mg zardaverine 0,018 (- 0.174.138) 0.041 (- 0.145-0.334) 
3.0 mg zardaverine 0.058 ( - 0.225-0.184) 0.074 (- 0.161-0.169) 
6.0 mg zardaverine 0.020 ( - 0~099-0~100) - 0.028 ( - 0.233-0.117) 
0.3 mg salbutamol 0.285 (0.041-0.460) 0.329 (0.069-0.472) 
Data are presented as median and 68% range in parentheses (n= 10). 
Table 2 Maximum increase in FEV, between active substance and placebo, time of occurrence 
and duration of increase by at least 10% compared to placebo 
Maximum increase Duration of 
Variable FEV, (1) Time of occurrence (min) increase (min) 
1.5 mg zardaverine 0.138 (- 0.085-0.440) 50 (20-210) 15 (O-101) 
3.0 mg zardaverine 0.166 ( - 0.065-0.323) 150 (6CL210) 58 (0 92) 
6.0 mg zardaverine 0.090 ( - 0.025-0.2 13) 150 (60-210) 20 (O-102) 
0.3 mg salbutamol 0.470 (0.163-0.673) 40 (30-150) 166 (48-230) 
Data are presented as median and 68% range in parentheses (n= IO). 
PDE V inhibitor zaprinast, the PDE III inhibitor 
enoximone, and the PDE III/IV inhibitor AH 21- 132 
were at least partially equivocal (8-10). 
Based on the IC,, values (concentration required 
for half maximum inhibition) for inhibition of selec- 
tive PDE isozymes, zardaverine shows more than 
loo-fold selectively for PDE III and PDE IV (3). 
Bronchodilation was demonstrated in vitro as well as 
in vivo in anaesthetized and conscious guinea pigs 
and in allergic sheep (3,4). Animal experiments 
suggest that, compared to theophylline, the broncho- 
dilatory effect of zardaverine is more pronounced 
(11). In addition, an anti-inflammatory potential of 
zardaverine has been demonstrated in vivo by the 
inhibition of bronchial cell infiltration following 
allergen challenge in sensitized guinea pigs (5). 
The aim of the present study was to investigate the 
bronchodilating efficacy of inhaled zardaverine in 
patients with chronic airflow obstruction, which 
was partially reversible after inhalation of a broncho- 
dilator. The results of the study clearly demonstrated 
that inhaled zardaverine, at doses up to 6.0 mg, in the 
double-blind part of the trial did not have a signifi- 
cant bronchodilatory effect. This contrasts with the 
pre-study reversibility test, in which a significant 
increase in FEV,, 30 min after inhalation of 6.0 mg 
zardaverine was observed. However, the time- 
averaged difference between the different doses of 
zardaverine and placebo over the 4-h study interval 
was neither clinically nor statistically significant. In 
contrast, inhaled salbutamol induced a significant 
bronchodilation in these patients. This emphasizes 
that to study the bronchodilating efficacy of a poten- 
tially weak bronchodilator, particularly in patients 
with only partially reversible airflow obstruction, it is 
necessary to look for time-averaged changes in lung 
function parameters rather than to concentrate on 
measurements at one single time point. 
A more pronounced bronchodilatory effect of 
zardaverine was observed in patients with a higher 
degree of reversibility of their airflow obstruction, 
after inhalation of a /3-sympathomimetic. For 
instance, in a study of allergic asthmatics, a modest 
and short-lasting bronchodilatation was observed 
after inhalation of 6.0 mg zardaverine (12). In 
another study, zardaverine significantly improved 
pulmonary function during the first hour of repeated 
inhalation (up to a total dose of 6.0 mg) (6). Again, 
the overall duration of bronchodilation was rather 
short and varied considerably between individual 
patients (6). 
The results from the present study, together with 
those from the two studies in asthmatics, clearly 
indicate that zardaverine is, at most, a weak broncho- 
dilator with a very limited duration of action. 
Obviously, the studies reported in man do not 
correlate with the promising findings in animal 
experiments. The most likely explanation for this 
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discrepancy is a very rapid clearance of inhaled 
zardaverine from the bronchial system (13). Another 
PDE III/IV inhibitor, the naphthyridine derivative 7. 
B9004-70, has a much longer duration of action than 8, 
zardaverine in animal experiments, and is currently 
under clinical investigation (13). 
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